Abstract
Proteins are the main actors in all physiological and pathological processes. Since the final structure of the protein does not depend on the DNA sequence or even the mRNA sequence alone, the search for direct approaches on the proteome has gained great interest. The most complex and probably the largest proteome is serum, making it clinically the most important.
ProteinChip technology, in combination with modern mass spectrometry, allows the complex search for biomarkers, molecular interactions, signaling pathways, and the identification of novel therapeutic compounds. Here we describe the surface-enhanced laser desorption-ionization (SELDI) in combination with the time-of-flight (TOF) mass spectrometry for analyzing serum samples (SELDI was a patented technique from Ciphergen, Fremont, CA). Aluminum-based arrays contain chemical or biological surfaces allowing the capture of proteins, which interact with the surface. The bound proteins are laser desorbed and ionized for mass spectroscopy analysis. The differential mass spectral patterns reflect the protein expression bound on the chip surface and allow the comparison between various samples. Proteins of interest can be identified using peptide mass fingerprinting (PME).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
1. Seet BT, Dikic I, Zho, MM, Pawson T (2006) Reading protein modifications with interaction domains. Nat Rev Mol Cell Biol 7:473–483
2. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. CeU 100:57–70
3. Gretzer MB, Partin AW, Chan DW, Veltri RW (2003) Modem tumor marker discovery in urology: Surface enhanced laser desorption and ionization (SELDI). Rev Urol 5:81–89
4. Ciordia S, de Los Rios V, Albar JP (2006) Contributions of advanced proteomics technologies to cancer diagnosis. Clin Transl Oncol 8:566–580
Wiesner A (2004) Detection of tumor markers with ProteinChip technology Curr Pharm Biotechnol 5:45–67
6. Xiao Z, Prieto D, Conrads TP, Veenstra TD, Issaq HJ (2005) Proteomic patterns: Their potential for disease diagnosis, Mol Cell Endocrinol 230:95–106
7. Zhang H, Kong B, Qu X, Jia L, Deng B, Yang Q (2006) Biomarker discovery for ovarian cancer using SELDI-TOF-MS. Gynecol Oncol 102:61–66
8. Pusztai L, Gregory BW, Baggerly KA, Peng B, Koomen J, Kuerer HM, Esteva FJ, Symmans WF, Wagner P, Hortobagyi GN, Laronga C, Semmes OJ, Wright G L Jr, Drake RR, Vlahou A (2004) Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer 100:1814–1822
9. Miguet L, Bogumil R, Decloquement P, Herbrecht R, Potier N, Mauvieux L, Van DA (2006) Discovery and identification of potential biomarkers in a prospective study of chronic lymphoid malignancies using SELDl-TOF-MS. J Proteome Res 5:2258–2269
Yip TT, Lomas L (2002) SELDI ProteinChip array in oncoproteomic research Technol Cancer Res Treat 1:273–280
11. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572–577
12. Ostergaard M, Rasmussen HH, Nielsen HV, Vorum H, Orntoft TF, Wolf H, Celis JE (1997) Proteome profiling of bladder squamous cell carcinomas: Identification of markers that define their degree of differentiation. Cancer Res 57:4111–4117
13. Anderson NL, Anderson NG (2002) The human plasma proteome: History, character, and diagnostic prospects. Mol Cell Proteomics 1:845–867
14. Anderson NL, Polanski M, Pieper R, Gatlin T, Tirumalai RS, Conrads TP, Veenstra TD, Adkins JN, Pounds JG, Fagan R, Lobley A (2004) The human plasma proteome: A nonredundant list developed by combination of four separate source. Mol Cell Proteomics 3:311–326
15. Issaq HJ, Conrads TP, Prieto DA, Tirumalai R, Veenstra TD (2003) SELDI-TOF MS for diagnostic proteomics. Anal Chem 75:148A–155A
16. Chapman K (2002) The ProteinChip Biomarker System from Ciphergen Biosystems: A novel proteomics platform for rapid biomarker discovery and validation. Biochem Soc Trans 30:82–87
17. Langbein S, Lehmann J, Harder A, Steidler A, Michel MS, Alken P, Badawi JK (2006) Protein profiling of bladder cancer using the 2D-PAGE and SELDI-TOF-MS technique. Technol Cancer Res Treat 5:67–72
18. Melle C, Ernst G, Schimmel B, Bleul A, Koscielny S, Wiesner A, Bogumil R, Moller U, Osterloh D, Halbhuber KJ, von Eggeling F. (2004) A technical triade for proteomic identification and characterization of cancer biomarkers. Cancer Res 64:4099–4104
19. Pusch W, Flocco MT, Leung SM, Thiele H, Kostrzewa M (2003) Mass spectrometry-based clinical proteomics. Pharmacogenomics 4:463–476
20. Fung FT, Weinberger SR, Gavin E, Zhang F (2005) Bioinformatics approaches in clinical proteomics. Expert Rev Proteomics 2:847–862
Acknowledgments
I thank Dr. R. Bogumil for his helpful advice and constructive criticism.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Langbein, S. (2008). Identification of Disease Biomarkers by Profiling of Serum Proteins Using SELDI-TOF Mass Spectrometry. In: Starkey, M., Elaswarapu, R. (eds) Genomics Protocols. Methods in Molecular Biology™, vol 439. Humana Press. https://doi.org/10.1007/978-1-59745-188-8_13
Download citation
DOI: https://doi.org/10.1007/978-1-59745-188-8_13
Publisher Name: Humana Press
Print ISBN: 978-1-58829-871-3
Online ISBN: 978-1-59745-188-8
eBook Packages: Springer Protocols